Clinical evidence indicates that high GPER expression is linked to a worse prognosis only in female patients with advanced CRC, not affecting survival in early-stage female patients or male patients at any stage (Bustos et al., 2017; Gilligan et al., 2017; Abancens et al., 2022; Lu et al., 2023). Here, GPER1 is linked to colorectal carcinoma.